Sep 2026· Frontiers in Bioscience· Vol 31 9, pp.
54751
· 0 citations· 27 references
Medicine
TL;DR
Findings suggest an association between altered cytokine signaling fibrocyte differentiation, and myelofibrosis in MDS.
Abstract
Background
The mechanism underlying myelofibrosis, which is associated with poor prognosis in myelodysplastic syndromes (MDS), remains unclear.
Methods
We investigated the mechanisms underlying myelofibrosis using peripheral blood mononuclear cells (PBMCs) from healthy donors, MDS92 cell culture supernatants and PolgA/+ and PolgA/A mice treated with high-dose romiplostim as an MDS model. We used the LEGENDplex™ immunoassay to analyze cytokine levels in MDS92 culture supernatants and serum samples from 12 patients with MDS or acute myeloid leukemia with myelodysplasia-related cytogenetic abnormalities.
Results
The MDS92 cell culture supernatants inhibited monocyte differentiation into fibrocytes and contained significantly lower levels of CXCL1 (C-X-C motif chemokine ligand 1), IL-6 (Interleukin-6), and CCL22 (C-C motif chemokine ligand 22) than PBMC culture supernatants from healthy donors. Among serum samples from patients with MDS, IL-18 level was positively correlated with myelofibrosis grade and splenomegaly. In PolgA/A mice, the F4/80high CD11blow/int cell fraction of the spleen was significantly increased following romiplostim administration, compared with PolgA/+ mice; however, worsening of splenomegaly was not observed. Furthermore, reticulin fibers were observed mainly in the subcortical region in all PolgA/+ mice but were rare in the PolgA/A mice.
Conclusions
These findings suggest an association between altered cytokine signaling fibrocyte differentiation, and myelofibrosis in MDS. Further studies are required to clarify how cytokine levels and cellular responsiveness contribute to fibrocyte-mediated myelofibrosis.
It is suggested that targeting inflammasome signaling may represent a potential therapeutic approach for MDS through deleting Asc, an adaptor protein that links inflammasome sensor proteins to caspase-1.
Clinical improvement, suppression of abnormal megakaryopoiesis, reduction in profibrotic signaling, and regression of bone marrow fibrosis should be assessed separately using measures matched to each therapeutic mechanism.
Jian-Song Huang, Xiao-Yue Yin, Xiao-Feng Shi et al.· Biomarker Research· 0 citations
Myelofibrosis (MF) is the aggressive end of the myeloproliferative neoplasm (MPN) spectrum, and its diagnosis and monitoring depend on bone marrow biopsy, which is invasive, subject to interobserver variability and frequently non-diagnostic. Here we profiled 564,147 circulating hematopoietic stem and progenitor cells (...
Gal Dadi, O. Milman, N. Furer et al.· bioRxiv· 0 citations
Dear Editor , In this study, we aimed to characterize IgG, IgM and complement fractions deposition in the BM of low-risk myelodysplastic syndrome (LR-MDS) 1 patients by immunohistochemistry and fl ow cytometry to assess the role of complement and humoral immunity on ineffective erythropoiesis and its clinical implicatio...
B. Fattizzo, G. Pedone, A. Zaninoni et al.· Signal Transduction and Targ...· 0 citations
Background: Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by clonal proliferation of immature myeloid cells, resulting in impaired normal hematopoiesis. Data on the hematological and immunophenotypic characteristics of AML in Yemeni patients remain limited.Objectives: This study a...
Monneer Hassan Hezaam, Mohammed Abdulkader Al-Nuzaili, Khaled Saad Al-Khamesy· مجلة جامعة صنعاء للطب والعلو...· 0 citations